Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-007080
Filing Date
2025-11-17
Accepted
2025-11-17 15:41:11
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13246
2 d12041703_ex99-a.htm EX-99 7602
3 d12041703_ex99-b.htm EX-99 884
  Complete submission text file 0000919574-25-007080.txt   23478
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Subject) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94441 | Film No.: 251490904
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1436 5TH STREET SUITE 3-210 MANHATTAN BEACH CA 90266
Business Address 1436 5TH STREET SUITE 3-210 MANHATTAN BEACH CA 90266 424-200-6630
GordonMD Global Investments LP (Filed by) CIK: 0002039349 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G